相关实验视频

Updated: Jun 6, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.8K

对小分子HPK1激酶抑制剂的最新审查 (2016年至今)

Yiping Duan1, Zhichao Guo1, Wenyi Zhong2

  • 1Department of Medicinal Chemistry, China Pharmaceutical University, School of Pharmacy, Nanjing, Jiangsu, 211198, Peoples Republic China.

Future medicinal chemistry
|November 25, 2024
PubMed
概括

造血基基因酶1 (HPK1) 抑制剂通过增强T细胞功能,显示出癌症免疫疗法的前景. 然而,目前的抑制剂会引起副作用,需要开发更有选择性的HPK1-向药物.

关键词:
这是一种HPK1抑制剂.T细胞耗尽的情况这是一种抗瘤药物.免疫疗法 免疫疗法小分子抑制剂小分子抑制剂

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K